Skip to main content
. 2023 Oct 17;15(10):2480. doi: 10.3390/pharmaceutics15102480

Table 2.

Summary of phototherapies by nanomedicines responsive to lower pH in the TME.

PS Photothermal Agent pH-Responsive Entity Function/Purpose Tumor Model In Vitro Tumor Model In Vivo Reference
MB IONPs Chitosan. Controlled drug release HeLa, A549 and MCF-7 cells BALB/c nude mice with A549 tumors [55]
ALA GNRs hydrazone bonds Controlled drug release MCF-7 cells Mice with MCF-7 tumors [56]
ICG ICG DMMA Enhanced cellular uptake HeLa cells / [57]
DPAE Cypate C/O@N-Micelle Enhanced tumor accumulation and improved cellular uptake 4T1 cells BALB/c mice with 4T1 tumors [58]
Ce6 PDA PAH-DMMA Enhanced cellular uptake MCF-7 cells / [59]
ICG ICG PEG-b-PAEMA-DMA Enhanced cellular uptake HNE-1 cells BALB/c mice with HNE-1 tumors [60]
CDs CDs MAA Enhanced cellular uptake 4T1 and MCF-7 cells Nude mice with 4T1 tumors [28]
Ce6 HAuNS pHLIP Drug release and cellular uptake Hela cells Nude mice with Hela tumors [61]
TBO MoS2 LA-K11 (DMA) Drug release and cellular uptake SCC-7 cells BALB/c nude mice with SCC-7 tumors [62]
BDPmPh, BDPbiPh and BDPtriPh NPs BDPmPh, BDPbiPh and BDPtriPh NPs Diethylamino groups Low pH-activated phototherapy HeLa cells Nude mice with HeLa tumors [63]